scholarly journals Long-term Effect of Transurethral Resection of Bladder Tumor Combined with Intravesical Instillation of Pirarubicin on Immune Function in Superficial Bladder Cancer

2020 ◽  
Vol 20 (s2) ◽  
Author(s):  
R. Feng
Keyword(s):  
Bladder Cancer ◽  
Immune Function ◽  
Transurethral Resection ◽  
Bladder Tumor ◽  
Superficial Bladder Cancer ◽  
Intravesical Instillation ◽  
Term Effect ◽  
Long Term Effect

scholarly journals Analysis of Japanese Patients Treated with or without Long-Term Epirubicin Plus Ara-C Intravesical Instillation Therapy for Low-Grade Superficial Bladder Cancer

2015 ◽  
Vol 2015 ◽  
pp. 1-5 ◽  
Author(s):  
Tomonori Kato ◽  
Kazushi Nomura ◽  
Fukuo Kondo ◽  
Masami Wakisaka ◽  
Akira Komiya
Keyword(s):  
Bladder Cancer ◽  
Tumor Recurrence ◽  
Superficial Bladder Cancer ◽  
Transitional Cell ◽  
Japanese Patients ◽  
Intravesical Instillation ◽  
Intravesical Chemotherapy ◽  
Low Grade ◽  
Free Rate

The high incidence of tumor recurrence following transurethral resection (TUR) represents a major problem encountered in the management of bladder cancer. This study examined the efficacy of intravesical chemotherapy in superficial bladder cancer. We retrospectively analyzed 90 Japanese cases with low-grade superficial transitional cell carcinoma (stage T1, grades 1 and 2) who were rendered tumor-free by TURBT (TUR of bladder tumor) and who thereafter were treated with or without intravesical chemotherapy. Among them, instillation was terminated in 2 patients due to adverse effects (severe but reversible chemical cystitis). Remaining 88 patients were divided into 2 groups according to therapy: the TURBT-only group(n=46), defined as patients treated with TURBT alone, and the Instillation group(n=42), defined as patients treated with weekly intravesical instillation therapies using epirubicin plus Ara-C. Recurrence-free rate was significantly higher in the Instillation group than in the TURBT-only group (p=0.02, HR = 0.457). The 5-year recurrence-free rate was 58.5% for the Instillation group and 38.6% for the TURBT-only group. Our instillation schedule represents the most intensive regimen among previously reported therapies and resulted in a 54.3% decrease in incidence of tumor recurrence. We believe that the results of this study could provide useful information on management of bladder cancer.

Evaluation of miR-146a Urinary Level as a Marker for Recurrence of Superficial Bladder Cancer after Transurethral Resection of Bladder Tumor (TUR-BT)

2020 ◽  
Vol 29 (3) ◽  
pp. 145-151
Author(s):  
Amany K. Shahat ◽  
Rabea G. Omar
Keyword(s):  
Bladder Cancer ◽  
Cancer Patients ◽  
Normal Level ◽  
Transurethral Resection ◽  
Cancer Biology ◽  
Bladder Tumor ◽  
Superficial Bladder Cancer ◽  
Urine Samples ◽  
Superficial Cancer

Background: The most prevalent malignancy affect the urinary system is bladder cancer which exhibits a markedly high recurrence rate. The level of urinary microRNA-146a (miR-146a) was significantly higher in superficial bladder cancer patients, and were decreased to normal range after transurethral resection of the bladder tumor (TUR-BT). Its level was increased again if there is recurrence of the superficial bladder tumor diagnosed by follow up cystoscopy. miR-146 may be a clinically important marker for diagnosis and recurrence of superficial bladder cancer and is used instead of follow up operations as follow up cystoscopy for follow up of recurrence . Objective: our work aims to detect a simple, reliable and noninvasive diagnostic and surveillance methods for follow up of superficial bladder cancer. Methodology: The level of miR-146a in urine of 30 superficial bladder cancer patients was evaluated by quantitative reverse transcription polymerase chain reaction assay using voided urine samples before, after TUR-BT and after 3, 6,9,12 months of resection and compared with the result of follow up cystoscopy. Results: miR-146a was significantly increased in urine samples from patients with superficial cancer bladder than in those from the normal individuals (P <.000). Elevated urinary miR-146a levels in patients with bladder cancer were lowered to the normal level after TUR-BT and increased again in those who have tumor recurrence and remain in a normal level in those who have no recurrence after follow up for 3 ,6, 9,12 months after surgery(P=. 007, P=.000 respectively).Conclusion: Our study concluded that urinary miR-146a may be useful as a novel noninvasive diagnostic and follow up marker, anticancer agent or therapeutic target for superficial cancer bladder, also for increasing our knowledge of cancer biology.

Sign in / Sign up

Export Citation Format

Share Document